Disparities in the participation and adherence of older adults in lifestyle-based multidomain dementia prevention and the motivational role of perceived disease risk and intervention benefits: an observational ancillary study to a randomised controlled trial

Nicola Coley, Delphine Coniasse-Brioude, Valérie Igier, Tristan Fournier, Jean-Pierre Poulain, Sandrine Andrieu, ACCEPT study group, Sandrine Andrieu, Nicola Coley, Virginie Gardette, Alain Grand, Valérie Igier, Delphine Coniasse Brioude, Maria Teresa Munoz Sastre, Jean Pierre Poulain, Tristan Fournier, Christelle Arandjelovic, Bruno Vellas, Stephane Oustric, Julie Subra, Nicola Coley, Delphine Coniasse-Brioude, Valérie Igier, Tristan Fournier, Jean-Pierre Poulain, Sandrine Andrieu, ACCEPT study group, Sandrine Andrieu, Nicola Coley, Virginie Gardette, Alain Grand, Valérie Igier, Delphine Coniasse Brioude, Maria Teresa Munoz Sastre, Jean Pierre Poulain, Tristan Fournier, Christelle Arandjelovic, Bruno Vellas, Stephane Oustric, Julie Subra

Abstract

Background: Preventive interventions for dementia are urgently needed and must be tested in randomised controlled trials (RCTs). Selection (volunteer) bias may limit efficacy, particularly in trials testing multidomain interventions and may also be indicative of disparities in intervention uptake in real-world settings. We identified factors associated with participation and adherence in a 3-year RCT of multidomain lifestyle intervention and/or omega-3 supplementation for prevention of cognitive decline and explored reasons for (non-) participation.

Methods: Ancillary study during recruitment and follow-up of the 3-year Multidomain Alzheimer Preventive Trial (MAPT) conducted in in 13 memory centres in France and Monaco, involving 1630 community-dwelling dementia-free individuals aged ≥ 70 who were pre-screened for MAPT (1270 participated in MAPT; 360 declined to participate).

Results: Response rates were 76% amongst MAPT participants and 53% amongst non-participants. Older individuals (odds ratio 0.94 [95% confidence interval 0.91-0.98] and those with higher anxiety (0.61 [0.47-0.79]) were less likely to participate in the trial. Those with higher income (4.42 [2.12-9.19]) and family history (1.60 [1.10-2.32]) or greater fear (1.73 [1.30-2.29]) of dementia were more likely to participate, as were those recruited via an intermediary (e.g. pension funds, local Alzheimer's associations, University of the 3rd Age, sports clubs) (2.15 [1.45-3.20]). MAPT participants living in larger towns (0.71 [0.55-0.92]) and with higher depressive symptoms (0.94 [0.90-0.99]) were less likely to adhere to the interventions. Greater perceived social support (1.21 [1.03-1.43]) and cognitive function (1.37 [1.13-1.67]) predicted better adherence. Descriptively, the most frequent reasons for accepting and refusing to participate were, respectively, altruism and logistical constraints, but underlying motivations mainly related to (lack of) perceived benefits.

Conclusions: Disparities in uptake of health interventions persist in older age. Those most at risk of dementia may not participate in or adhere to preventive interventions. Barriers to implementing lifestyle changes for dementia prevention include lack of knowledge about potential benefits, lack of support networks, and (perceived) financial costs.

Trial registration: NCT00672685 (ClinicalTrials.gov).

Keywords: Adherence; Disparities; Engagement; Intervention; Lifestyle; Multidomain; Participation; Population bias; Prevention.

Conflict of interest statement

SA reports grants from EU programs, Fondation de l’Avenir, and the AMPA and France Alzheimer Associations; personal fees from Nestlé, Nestec SA, Sanofi, and MSD; and non-financial support from Biogen, Pfizer, and Icon outside the submitted work. The other authors have no competing interests.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Flowchart. Adherence was defined as the proportion of participants completing ≥ 75% of their assigned interventions (calculated over the entire 3-year follow-up period, regardless of dropout status, except for participants who died or dropped out due to medical reasons, for whom the adherence rate was calculated only until the time of dropout). Adherence could not be calculated for some participants due to missing data (primarily regarding adherence to the omega-3 supplement/placebo). Superscript lowercase letter ‘a’ indicates inclusion visit not planned or not attended; superscript lowercase letter ‘b’ indicates including 8 subjects who did not attend the 3-year visit but who may have continued into the extended follow-up period
Fig. 2
Fig. 2
Reasons for accepting and refusing to participate in the MAPT trial. a Reasons for accepting: percentage of participants who declared that they completely agreed that this was a reason for participating in the MAPT trial (N = 1251). b Reasons for refusing: percentage of non-participants who declared that they completely agreed that this was a reason for not participating in the MAPT trial (N = 317)

References

    1. G. B. D. Dementia Collaborators GBDD. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(1):88–106. 10.1016/S1474-4422(18)30403-4.
    1. Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, Brayne C, Burns A, Cohen-Mansfield J, Cooper C, Costafreda SG, Dias A, Fox N, Gitlin LN, Howard R, Kales HC, Kivimäki M, Larson EB, Ogunniyi A, Orgeta V, Ritchie K, Rockwood K, Sampson EL, Samus Q, Schneider LS, Selbæk G, Teri L, Mukadam N. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413–446. doi: 10.1016/S0140-6736(20)30367-6.
    1. Andrieu S, Coley N, Lovestone S, Aisen PS, Vellas B. Prevention of sporadic Alzheimer’s disease: lessons learned from clinical trials and future directions. Lancet Neurol. 2015;14(9):926–944. doi: 10.1016/S1474-4422(15)00153-2.
    1. Kivipelto M, Mangialasche F, Ngandu T, World Wide Fingers N. World Wide Fingers will advance dementia prevention. Lancet Neurol. 2018;17(1):27. doi: 10.1016/S1474-4422(17)30431-3.
    1. Andrieu S, Guyonnet S, Coley N, Cantet C, Bonnefoy M, Bordes S, Bories L, Cufi MN, Dantoine T, Dartigues JF, Desclaux F, Gabelle A, Gasnier Y, Pesce A, Sudres K, Touchon J, Robert P, Rouaud O, Legrand P, Payoux P, Caubere JP, Weiner M, Carrié I, Ousset PJ, Vellas B, Vellas B, Guyonnet S, Carrié I, Brigitte L, Faisant C, Lala F, Delrieu J, Villars H, Combrouze E, Badufle C, Zueras A, Andrieu S, Cantet C, Morin C, van Kan GA, Dupuy C, Rolland Y, Caillaud C, Ousset PJ, Fougère B, Willis S, Belleville S, Gilbert B, Fontaine F, Dartigues JF, Marcet I, Delva F, Foubert A, Cerda S, Noëlle-Cuffi M, Costes C, Rouaud O, Manckoundia P, Quipourt V, Marilier S, Franon E, Bories L, Pader ML, Basset MF, Lapoujade B, Faure V, Li M, Tong Y, Malick-Loiseau C, Cazaban-Campistron E, Desclaux F, Blatge C, Dantoine T, Laubarie-Mouret C, Saulnier I, Clément JP, Picat MA, Bernard-Bourzeix L, Willebois S, Désormais I, Cardinaud N, Bonnefoy M, Livet P, Rebaudet P, Gédéon C, Burdet C, Terracol F, Pesce A, Roth S, Chaillou S, Louchart S, Sudres K, Lebrun N, Barro-Belaygues N, Touchon J, Bennys K, Gabelle A, Romano A, Touati L, Marelli C, Pays C, Robert P, le Duff F, Gervais C, Gonfrier S, Gasnier Y, Bordes S, Begorre D, Carpuat C, Khales K, Lefebvre JF, el Idrissi SM, Skolil P, Salles JP, Dufouil C, Lehéricy S, Chupin M, Mangin JF, Bouhayia A, Allard M, Ricolfi F, Dubois D, Paule M, Martel B, Cotton F, Bonafé A, Chanalet S, Hugon F, Bonneville F, Cognard C, Chollet F, Payoux P, Voisin T, Peiffer S, Hitzel A, Allard M, Zanca M, Monteil J, Darcourt J, Molinier L, Derumeaux H, Costa N, Vincent C, Perret B, Vinel C, Olivier-Abbal P. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol. 2017;16(5):377–389. doi: 10.1016/S1474-4422(17)30040-6.
    1. Moll van Charante EP, Richard E, Eurelings LS, et al. Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a cluster-randomised controlled trial. Lancet. 2016;388(10046):797–805. doi: 10.1016/S0140-6736(16)30950-3.
    1. Ngandu T, Lehtisalo J, Solomon A, Levälahti E, Ahtiluoto S, Antikainen R, Bäckman L, Hänninen T, Jula A, Laatikainen T, Lindström J, Mangialasche F, Paajanen T, Pajala S, Peltonen M, Rauramaa R, Stigsdotter-Neely A, Strandberg T, Tuomilehto J, Soininen H, Kivipelto M. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255–2263. doi: 10.1016/S0140-6736(15)60461-5.
    1. Prindle JJ, McArdle JJ. How representative is the ACTIVE sample? A statistical comparison of the ACTIVE sample and the HRS sample. J Aging Health. 2013;25(8 Suppl):85S–102S. doi: 10.1177/0898264313497795.
    1. Beishuizen CRL, Coley N. Moll van Charante EP, van Gool WA, Richard E, Andrieu S. Determinants of dropout and nonadherence in a dementia prevention randomized controlled trial: the prevention of dementia by intensive vascular care trial. J Am Geriatr Soc. 2017;65(7):1505–1513. doi: 10.1111/jgs.14834.
    1. Coley N, Ngandu T, Lehtisalo J, Soininen H, Vellas B, Richard E, Kivipelto M, Andrieu S, HATICE, FINGER, and MAPT/DSA groups Adherence to multidomain interventions for dementia prevention: Data from the FINGER and MAPT trials. Alzheimers Dement. 2019;15(6):729–741. doi: 10.1016/j.jalz.2019.03.005.
    1. Dodge HH, Katsumata Y, Zhu J, Mattek N, Bowman M, Gregor M, Wild K, Kaye JA. Characteristics associated with willingness to participate in a randomized controlled behavioral clinical trial using home-based personal computers and a webcam. Trials. 2014;15(1):508. doi: 10.1186/1745-6215-15-508.
    1. Fitzpatrick AL, Fried LP, Williamson J, Crowley P, Posey D, Kwong L, Bonk J, Moyer R, Chabot J, Kidoguchi L, Furberg CD, DeKosky S, GEM Study Investigators Recruitment of the elderly into a pharmacologic prevention trial: the Ginkgo Evaluation of Memory Study experience. Contemp Clin Trials. 2006;27(6):541–553. doi: 10.1016/j.cct.2006.06.007.
    1. Ngandu T, Lehtisalo J, Levalahti E, et al. Recruitment and baseline characteristics of participants in the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER)-a randomized controlled lifestyle trial. Int J Environ Res Public Health. 2014;11(9):9345–9360. doi: 10.3390/ijerph110909345.
    1. Rosenstock IM. The Health Belief Model and Preventive Health Behavior. Health Educ Monographs. 1974;2(35-86).
    1. Andrieu S, Coley N, Gardette V, Subra J, Oustric S, Fournier T, Poulain JP, Coniasse-Brioude D, Igier V, Vellas B, Grand A. Representations and practices of prevention in elderly populations: investigating acceptance to participate in and adhesion to an intervention study for the prevention of Alzheimer’s disease (ACCEPT study)--the need for a multidisciplinary approach. J Nutr Health Aging. 2012;16(4):352–354. doi: 10.1007/s12603-012-0045-9.
    1. Prom-Wormley EC, Clifford JS, Bourdon JL, et al. Developing community-based health education strategies with family history: assessing the association between community resident family history and interest in health education. Soc Sci Med. 2019:112160.
    1. Wardle J, Sutton S, Williamson S, Taylor T, McCaffery K, Cuzick J, Hart A, Atkin W. Psychosocial influences on older adults’ interest in participating in bowel cancer screening. Prev Med. 2000;31(4):323–334. doi: 10.1006/pmed.2000.0725.
    1. Ding EL, Powe NR, Manson JE, Sherber NS, Braunstein JB. Sex differences in perceived risks, distrust, and willingness to participate in clinical trials: a randomized study of cardiovascular prevention trials. Arch Intern Med. 2007;167(9):905–912. doi: 10.1001/archinte.167.9.905.
    1. Smith BJ, Ali S, Quach H. The motivation and actions of Australians concerning brain health and dementia risk reduction. Health Promot J Austr. 2015;26(2):115–121. doi: 10.1071/HE14111.
    1. Coley N, Rosenberg A, van Middelaar T, et al. Older adults’ reasons for participating in an eHealth prevention trial: a cross-country, mixed-methods comparison. J Am Med Dir Assoc. 2018.
    1. Kelly S, Martin S, Kuhn I, Cowan A, Brayne C, Lafortune L. Barriers and facilitators to the uptake and maintenance of healthy behaviours by people at mid-life: a rapid systematic review. PLoS One. 2016;11(1):e0145074. doi: 10.1371/journal.pone.0145074.
    1. Fratiglioni L, Paillard-Borg S, Winblad B. An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol. 2004;3(6):343–353. doi: 10.1016/S1474-4422(04)00767-7.
    1. Tolmie EP, Mungall MM, Louden G, Lindsay GM, Gaw A. Understanding why older people participate in clinical trials: the experience of the Scottish PROSPER participants. Age Ageing. 2004;33(4):374–378. doi: 10.1093/ageing/afh109.
    1. Welton AJ, Vickers MR, Cooper JA, Meade TW, Marteau TM. Is recruitment more difficult with a placebo arm in randomised controlled trials? A quasirandomised, interview based study. BMJ. 1999;318(7191):1114–1117. doi: 10.1136/bmj.318.7191.1114.
    1. Parial LL, Lam SC, Ho JYS, Suen LKP, Leung AYM. Public knowledge of the influence of modifiable cardiovascular risk factors on dementia: a systematic literature review and meta-analysis. Aging Mental Health. 2021;25(8):1395–1409. doi: 10.1080/13607863.2020.1786801.
    1. Anstey KJ, Peters R. Oversimplification of dementia risk reduction messaging is a threat to knowledge translation in dementia prevention research. J Prev Alzheimers Dis. 2018;5(1):2–4. doi: 10.14283/jpad.2017.27.
    1. Roberts JS, McLaughlin SJ, Connell CM. Public beliefs and knowledge about risk and protective factors for Alzheimer’s disease. Alzheimers Dement. 2014;10(5 Suppl):S381–S389. doi: 10.1016/j.jalz.2013.07.001.
    1. Boles M, Getchell WS, Feldman G, McBride R, Hart RG. Primary prevention studies and the healthy elderly: evaluating barriers to recruitment. J Community Health. 2000;25(4):279–292. doi: 10.1023/A:1005153909429.
    1. Martin KA, Sinden AR. Who will stay and who will go? A review of older adults’ adherence to randomized controlled trials of exercise. J Aging Phys Act. 2001;9(2):91–114. doi: 10.1123/japa.9.2.91.
    1. Clarke P, Nieuwenhuijsen ER. Environments for healthy ageing: a critical review. Maturitas. 2009;64(1):14–19. doi: 10.1016/j.maturitas.2009.07.011.
    1. Kinderman P, Schwannauer M, Pontin E, Tai S. Psychological processes mediate the impact of familial risk, social circumstances and life events on mental health. PLoS One. 2013;8(10):e76564. doi: 10.1371/journal.pone.0076564.
    1. Phillips J, Ajrouch K, Hillcoat-Nalletamby S. Key concepts in social gerontology. Los Angeles: Sage; 2010.
    1. Risk reduction of cognitive decline and dementia. WHO guidelines. Geneva: World Health Organization; 2019. ISBN-13: 978-92-4-155054-3.

Source: PubMed

3
S'abonner